Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.

Publication date: Feb 26, 2024

Real-world vaccine effectiveness following the third dose of vaccination against SARS-CoV-2 remains less investigated among people with HIV (PWH). PWH receiving the third dose of BNT162b2 and mRNA-1273 (either 50- or 100-μg) were enrolled. Participants were followed for 180 days until the fourth dose of COVID-19 vaccination, SARS-CoV-2 infection, seroconversion of anti-nucleocapsid IgG, death, or loss to follow-up. Anti-spike IgG was determined every 1-3 months. Of 1427 participants undergoing the third-dose COVID-19 vaccination, 632 (44. 3%) received 100-μg mRNA-1273, 467 (32. 8%) 50-μg mRNA-1273, and 328 (23. 0%) BNT162b2 vaccine and the respective rate of SARS-CoV-2 infection or seroconversion of anti-nucleocapsid IgG was 246. 1, 280. 8 and 245. 2 per 1000 person-months of follow-up (log-rank test, p = 0. 28). Factors associated with achieving anti-S IgG titers >1047 BAU/mL included CD4 count 200 copies/mL (aOR, 0. 27; 95% CI, 0. 09-0. 80), having achieved anti-spike IgG >141 BAU/mL within 3 months after primary vaccination (aOR, 3. 69; 95% CI, 2. 68-5. 07), receiving BNT162b2 vaccine as the third dose (aOR, 0. 20; 95% CI, 0. 10-0. 41; reference, 100-μg mRNA-1273), and having previously received two doses of mRNA vaccine in primary vaccination (aOR, 2. 46; 95% CI, 1,75-3. 45; reference, no exposure to mRNA vaccine). PWH receiving different types of the third dose of COVID-19 vaccine showed similar vaccine effectiveness against SARS-CoV-2 infection. An additional dose with 100-μg mRNA-1273 could generate a higher antibody response than with 50-μg mRNA-1273 and BNT162b2 vaccine.

Concepts Keywords
Bnt162b2 BNT162b2 vaccine
Death Booster vaccination
Hiv Humoral immunity
Vaccination Immunogenicity
mRNA-1273 vaccine
Serologic response

Semantics

Type Source Name
disease VO effectiveness
disease MESH COVID-19
disease VO vaccination
disease VO vaccine effectiveness
disease VO dose
pathway REACTOME SARS-CoV-2 Infection
disease MESH seroconversion
disease MESH death
disease VO vaccine
disease VO primary vaccination
disease VO COVID-19 vaccine

Original Article

(Visited 1 times, 1 visits today)